MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET

Company Participants

Zack Armen - Head, Investor Relations
Jennifer Buell - President and Chief Executive Officer
Marc Van Dijk - Chief Scientific Officer
Christine Klaskin - Principal Financial and Accounting Officer

Conference Call Participants

Emily Bodnar - H.C. Wainwright
Jack Allen - Baird
Mayank Mamtani - B. Riley
Matthew Phipps - William Blair

Operator

Good morning and welcome to MiNK Therapeutics Second Quarter 2024 Conference Call and Webcast. All participants will be in listen-only mode until question-and-answer session. Please note this event is being recorded. If anyone has any objection, you may now disconnect at this time.

I would now like to turn to conference [technical difficulty] Zack Armen, Investor Relations.

Zack Armen

Thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you [technical difficulty] including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.

Joining me today are Dr. Jen Buell, President and Chief Executive Officer; Dr. Marc Van Dijk, Chief Scientific Officer; Dr. Joy Zhou, Head of CMC, and Christine Klaskin, Principal Financial and Accounting Officer.

Now I'd like to turn the call over to Dr. Buell to highlight our progress on this quarter.

Jennifer Buell

Thank you, Zach. Good morning, and thanks for joining us today. I'm excited to share the strides we've made in the first half of 2024 as we continue to align our achievements with our long-term strategic goals. And For those of you new to the story at MiNK, our mission is focused on delivering the immune potent potential of invariant natural killer T cells to [tackle diseases] (ph) of the immune system and cancer.

Today I'll be highlighting our latest clinical developments, particularly in our lead programs, AgenT-797. These are native, unmodified iNKT cells, and MiNK-215, our armored FAP CAR-iNKT. Additionally, I'll discuss how we've fortified our financial foundation, setting the stage for sustained innovation and growth. We've made substantial progress in streamlining our operations to optimize our financials in this market.

In this quarter, we continue to generate critical data from our ongoing clinical programs. We continue to advance our R&D efforts and ensure efficient in-house manufacturing all the while appreciating further reductions to our operating burn. Now reduced more than 50% from this time last year, mainly from the internalization of key activities. These reductions have been a result of the internalization of our efforts and continued external financial support to advance our exciting programs.